Ghrelin Promotes Functional Angiogenesis in a Mouse Model of Critical Limb Ischemia Through Activation of Proangiogenic MicroRNAs
- 16 December 2015
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 157 (2) , 432-445
Abstract
Current therapeutic strategies for the treatment of critical limb ischemia (CLI) have only limited success. Recent in vitro evidence in the literature, using cell lines, proposes that the peptide hormone ghrelin may have angiogenic properties. In this study, we aim to investigate if ghrelin could promote postischemic angiogenesis in a mouse model of CLI and, further, identify the mechanistic pathway(s) that underpin ghrelin's proangiogenic properties. CLI was induced in male CD1 mice by femoral artery ligation. Animals were then randomized to receive either vehicle or acylated ghrelin (150 μg/kg sc) for 14 consecutive days. Subsequently, synchrotron radiation microangiography was used to assess hindlimb perfusion. Subsequent tissue samples were collected for molecular and histological analysis. Ghrelin treatment markedly improved limb perfusion by promoting the generation of new capillaries and arterioles (internal diameter less than 50 μm) within the ischemic hindlimb that were both structurally and functionally normal; evident by robust endothelium-dependent vasodilatory responses to acetylcholine. Molecular analysis revealed that ghrelin's angiogenic properties were linked to activation of prosurvival Akt/vascular endothelial growth factor/Bcl-2 signaling cascade, thus reducing the apoptotic cell death and subsequent fibrosis. Further, ghrelin treatment activated proangiogenic (miR-126 and miR-132) and antifibrotic (miR-30a) microRNAs (miRs) while inhibiting antiangiogenic (miR-92a and miR-206) miRs. Importantly, in vitro knockdown of key proangiogenic miRs (miR-126 and miR-132) inhibited the angiogenic potential of ghrelin. These results therefore suggest that clinical use of ghrelin for the early treatment of CLI may be a promising and potent inducer of reparative vascularization through modulation of key molecular factors.Keywords
This publication has 62 references indexed in Scilit:
- Therapeutic angiogenesis for critical limb ischaemiaNature Reviews Cardiology, 2013
- VEGF gene therapy: therapeutic angiogenesis in the clinic and beyondGene Therapy, 2012
- Autologous bone marrow cell therapy for patients with peripheral arterial disease: a meta-analysis of randomized controlled trialsExpert Opinion on Biological Therapy, 2011
- FACS‐purified myoblasts producing controlled VEGF levels induce safe and stable angiogenesis in chronic hind limb ischemiaJournal of Cellular and Molecular Medicine, 2011
- Exogenous Ghrelin Attenuates the Progression of Chronic Hypoxia-Induced Pulmonary Hypertension in Conscious RatsEndocrinology, 2007
- Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)Journal of Vascular Surgery, 2007
- Ghrelin improves left ventricular dysfunction and cardiac cachexia in heart failureCurrent Opinion in Pharmacology, 2003
- Chronic Administration of Ghrelin Improves Left Ventricular Dysfunction and Attenuates Development of Cardiac Cachexia in Rats With Heart FailureCirculation, 2001
- Chronic lower limb ischemiaWestern Journal of Medicine, 2000
- Ghrelin is a growth-hormone-releasing acylated peptide from stomachNature, 1999